JP7526783B2 - 癌を処置する方法 - Google Patents

癌を処置する方法 Download PDF

Info

Publication number
JP7526783B2
JP7526783B2 JP2022507799A JP2022507799A JP7526783B2 JP 7526783 B2 JP7526783 B2 JP 7526783B2 JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022507799 A JP2022507799 A JP 2022507799A JP 7526783 B2 JP7526783 B2 JP 7526783B2
Authority
JP
Japan
Prior art keywords
acceptable salt
dose
pharma
cfg920
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543679A (ja
JP2022543679A5 (https=
JPWO2021026454A5 (https=
Inventor
ルー，クリス
ジャン，ルイポン
ユエ，ヨン
ジャン，ミンホア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laekna Ltd
Original Assignee
Laekna Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekna Ltd filed Critical Laekna Ltd
Publication of JP2022543679A publication Critical patent/JP2022543679A/ja
Publication of JP2022543679A5 publication Critical patent/JP2022543679A5/ja
Publication of JPWO2021026454A5 publication Critical patent/JPWO2021026454A5/ja
Application granted granted Critical
Publication of JP7526783B2 publication Critical patent/JP7526783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2022507799A 2019-08-08 2020-08-07 癌を処置する方法 Active JP7526783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019099754 2019-08-08
CNPCT/CN2019/099754 2019-08-08
PCT/US2020/045410 WO2021026454A1 (en) 2019-08-08 2020-08-07 Method of treating cancer

Publications (4)

Publication Number Publication Date
JP2022543679A JP2022543679A (ja) 2022-10-13
JP2022543679A5 JP2022543679A5 (https=) 2023-08-10
JPWO2021026454A5 JPWO2021026454A5 (https=) 2023-08-10
JP7526783B2 true JP7526783B2 (ja) 2024-08-01

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507799A Active JP7526783B2 (ja) 2019-08-08 2020-08-07 癌を処置する方法

Country Status (12)

Country Link
US (2) US20210038578A1 (https=)
EP (1) EP4009969A1 (https=)
JP (1) JP7526783B2 (https=)
KR (1) KR20220047589A (https=)
CN (1) CN114080225A (https=)
AU (1) AU2020327022B2 (https=)
BR (1) BR112022001508A2 (https=)
CA (1) CA3148115A1 (https=)
IL (1) IL289811A (https=)
MX (1) MX2022001450A (https=)
TW (1) TWI857119B (https=)
WO (1) WO2021026454A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
US20250032504A1 (en) * 2021-11-27 2025-01-30 Transthera Sciences (Nanjing), Inc. Novel application of kinase inhibitor
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531884A (ja) 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110288142A1 (en) * 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UY32730A (es) * 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
US10265329B2 (en) * 2015-03-06 2019-04-23 The Cleveland Clinic Foundation Altering steroid metabolism for treatment of steroid-dependent disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531884A (ja) 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2016年，Vol.27, Suppl.6，VI243
Molecular Cancer Therapeutics，2015年，Vol.14, No.12, Suppl.2，B29
Steroids，2015年，Vol.95，p.80-87

Also Published As

Publication number Publication date
US20250090514A1 (en) 2025-03-20
JP2022543679A (ja) 2022-10-13
AU2020327022A8 (en) 2022-06-30
WO2021026454A1 (en) 2021-02-11
AU2020327022A1 (en) 2022-02-10
KR20220047589A (ko) 2022-04-18
TWI857119B (zh) 2024-10-01
AU2020327022B2 (en) 2025-12-18
BR112022001508A2 (pt) 2022-07-12
MX2022001450A (es) 2022-04-20
TW202120086A (zh) 2021-06-01
EP4009969A1 (en) 2022-06-15
CN114080225A (zh) 2022-02-22
CA3148115A1 (en) 2021-02-11
US20210038578A1 (en) 2021-02-11
IL289811A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US20250090514A1 (en) Method of treating cancer
CN113164500A (zh) 治疗去势抵抗性和去势敏感性前列腺癌的方法
JP2020507610A (ja) 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
EP2694074B1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20210137890A1 (en) Deuterated imidazolidinedione compounds and their uses
EP3808345A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
TW202434251A (zh) 治療癌症之療法
EA049014B1 (ru) Способ лечения рака
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
AU2023356291A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
JP2026000999A (ja) 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2023059714A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40098285A (zh) 用於治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
CA3230285A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240722

R150 Certificate of patent or registration of utility model

Ref document number: 7526783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150